Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 6 | 2018 | 1828 | 0.500 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2013 | 23 | 0.400 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 39 | 0.390 |
Why?
|
| Receptor, Notch1 | 3 | 2018 | 76 | 0.380 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 251 | 0.360 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 376 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 634 | 0.310 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 629 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 607 | 0.170 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 36 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 727 | 0.130 |
Why?
|
| Ephrin-B2 | 1 | 2016 | 9 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 127 | 0.130 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2016 | 31 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2018 | 200 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2018 | 998 | 0.130 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2016 | 61 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 816 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2018 | 1035 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2018 | 330 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2018 | 418 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 29 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 62 | 0.110 |
Why?
|
| Anilides | 1 | 2014 | 58 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2016 | 880 | 0.110 |
Why?
|
| Neoplasms | 3 | 2018 | 2953 | 0.100 |
Why?
|
| Gene Dosage | 1 | 2015 | 449 | 0.100 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 1683 | 0.100 |
Why?
|
| Pyridines | 1 | 2014 | 249 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 60 | 0.100 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 63 | 0.100 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2012 | 12 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 87 | 0.100 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2012 | 44 | 0.090 |
Why?
|
| Pyrimidinones | 1 | 2012 | 60 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 445 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 540 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1303 | 0.090 |
Why?
|
| Pyridones | 1 | 2012 | 130 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 615 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2018 | 755 | 0.090 |
Why?
|
| Mutation | 2 | 2016 | 6245 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 764 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1033 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 772 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 722 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2674 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2009 | 168 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 1381 | 0.060 |
Why?
|
| Prognosis | 4 | 2018 | 5004 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2018 | 174 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2004 | 38 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2018 | 226 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1993 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 1577 | 0.050 |
Why?
|
| Middle Aged | 7 | 2020 | 28893 | 0.050 |
Why?
|
| Aged | 6 | 2020 | 21394 | 0.050 |
Why?
|
| Mice | 6 | 2018 | 18534 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1346 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 300 | 0.050 |
Why?
|
| Male | 8 | 2018 | 64846 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 402 | 0.050 |
Why?
|
| Female | 10 | 2020 | 70607 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 955 | 0.040 |
Why?
|
| Animals | 7 | 2018 | 34908 | 0.040 |
Why?
|
| Colorado | 1 | 2020 | 21 | 0.040 |
Why?
|
| Humans | 11 | 2020 | 131930 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 69 | 0.040 |
Why?
|
| Adult | 6 | 2020 | 31506 | 0.040 |
Why?
|
| Apoptosis | 2 | 2018 | 1900 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2016 | 1569 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 3688 | 0.040 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 6 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 9 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 6435 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2018 | 383 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2020 | 3710 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 608 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 37 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 7113 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2015 | 54 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 996 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 61 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 825 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1668 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 84 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 10893 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 794 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 333 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 295 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1124 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 370 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 2183 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 257 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1719 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1450 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 343 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2015 | 4717 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 131 | 0.020 |
Why?
|
| Half-Life | 1 | 2012 | 161 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 4688 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 503 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 319 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2509 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 175 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2303 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 749 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2020 | 17345 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 699 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2009 | 34 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 84 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1876 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5394 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 2061 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5143 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2009 | 149 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 12996 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1288 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 226 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 662 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1596 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4538 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1294 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3358 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1363 | 0.010 |
Why?
|
| United States | 2 | 2012 | 11619 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2004 | 274 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 203 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1303 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 9929 | 0.010 |
Why?
|